MIAMI BEACH, Fla.,
June 26, 2012 /PRNewswire/ -- Divine Skin Inc. (DSKX) (OTC Bulletin Board: DSKX) Divine Skin today announced that it was granted a Drug Enforcement Agency license in partnership with its manufacturing partner to produce and distribute Ephedrine containing drugs and other controlled substances.
The Company has started working on a new OTC analgesic, which it believes could provide an alternative to current OTC pain relievers. Receiving this mandatory license is the final step in commencing manufacturing of its OTC pain reliever.
the United States alone, manufacturers' revenue from internal non-narcotic analgesics, antipyretics, anti-arthritics, and anti-inflammatories, including salicylates and acetaminophen, totaled
$2.4 billion in 2009, according to an
August 2010 report published by the US Census Bureau.
About Divine Skin
Divine Skin Inc. is a leader in the development of biotechnology for topical, nutritional, and pharmaceutical therapies. It markets worldwide through online and specialty retailers, cosmetics wholesalers, salons, and medical offices.
DS Laboratories, its flagship brand, offers high-performance topical solutions for a wide range of personal care needs. Bioavailability is enhanced through Nanosome encapsulation (
The Sigma Skin brand sells through upscale retailers like
the United States
. The topical products address hair loss and other signs of aging (SigmaSkin.com).
Polaris Research Laboratories makes high-potency hair-growth formulas (Polarisresearchlabs.com).
The Pure Guild offers purity with performance: Botanical compounds proven effective in clinical trials are extracted without industrial solvents or damaging heat and are sold through premium retailers. (ThePureGuild.com).
Except for statements of historical fact, the matters discussed in this press release are forward-looking and made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "future," "plan" or "planned," "expects," or "projected." These forward-looking statements reflect numerous assumptions and involve a variety of risks and uncertainties, many of which are beyond the company's control that may cause actual results to differ materially from stated expectations. These risk factors include, among others, limited operating history, difficulty in developing and marketing products, intense competition and additional risks factors as discussed in reports filed by the company with the Securities and Exchange Commission, which are available at
Investor Relations Divine Skin Inc.1.407.342.4112